Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Controlled Clinical Trial
. 2007 Apr;91(4):449-54.
doi: 10.1136/bjo.2006.106336. Epub 2006 Oct 31.

Pretreatment of posterior subtenon injection of triamcinolone acetonide has beneficial effects for grid pattern photocoagulation against diffuse diabetic macular oedema

Affiliations
Controlled Clinical Trial

Pretreatment of posterior subtenon injection of triamcinolone acetonide has beneficial effects for grid pattern photocoagulation against diffuse diabetic macular oedema

Masahiko Shimura et al. Br J Ophthalmol. 2007 Apr.

Abstract

Aim: To prospectively evaluate the efficacy of subtenon injection of triamcinolone acetonide (TA) before laser grid pattern photocoagulation (G-PC) for the treatment of diffuse diabetic macular oedema (DDME).

Methods: 42 eyes of 37 consecutive patients with DDME were studied. 1 week before G-PC, 21 eyes received TA subtenon injection, and the other eyes served as control. The clinical course of visual acuity (VA) and foveal thickness (FT) was monitored for up to 24 weeks after G-PC. Mean deviation (MD) of perimetry with 30-2 program on Humphrey Perimeter (Zeiss-Humphrey, Dublin, California, USA) was also measured. The average laser intensity was recorded.

Results: After TA injection, FT and VA were improved, and subsequent G-PC maintained the improvement for up to 24 weeks without recurrence of diffuse diabetic macular oedema. In contrast, G-PC without TA injection induced transient worsening of FT and VA, then both were gradually improved. At 24 weeks after G-PC, MD in the TA-injected eyes was better than those in control. The required laser intensity in TA-injected eyes was less than that for control.

Conclusion: Subtenon injection of TA prior to G-PC allows for treatment with a lower intensity of laser spots and also prevents the decrease in central visual field sensitivity, all of which have clinical advantages for G-PC.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None.

Comment in

Similar articles

Cited by

References

    1. Moss S E, Klein R, Klein B E K. The incidence of visual loss in a diabetic population. Ophthalmology 1988951340–1348. - PubMed
    1. MacMeel J W, Trempe C L, Franks E B. Diabetic maculopathy. Trans Am Acad Ophthalmol Otolaryngol 197783476–487. - PubMed
    1. Early Treatment Diabetic Retinopathy Study Research Group Focal photocoagulation treatment of diabetic macular edema. Report number 19. Arch Ophthalmol 19951131144–1155. - PubMed
    1. Early Treatment Diabetic Retinopathy Study Research Group Photocoagulation for diabetic macular edema. Report #1. Arch Ophthalmol 19851031796–1806. - PubMed
    1. Early Treatment Diabetic Retinopathy Study Research Group Treatmant. Techniques and clinical guidelines for photocoagulation of diabetic macular edema. Report #2. Ophthalmology 198794761–774. - PubMed

Publication types

MeSH terms